secwatch.observer — SEC 8-K summary
======================================

Issuer:     60 DEGREES PHARMACEUTICALS, INC. (SXTP)
CIK:        0001946563
Form:       8-K
Filed at:   2023-09-18T23:59:59+00:00
Accession:  0001213900-23-077357
Event type: other_material
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

60 Degrees Pharma withdraws COVID Phase IIB IND after FDA comments; will resubmit pending feasibility
--------------------------------------------------------------------------------

- Withdrew IND for ACLR8-LR Phase IIB study of tafenoquine for COVID-19 due to FDA comments on study design.
- Plans to submit revised IND in Q4 2023 pending assessment of feasibility to meet FDA expectations.
- Paused start-up activities for the trial, decreasing short-term burn rate and improving cash position.
- Will continue commercialization of ARAKODA (tafenoquine) for malaria and prepare IND for babesiosis.
- Q2 2023 ARAKODA sales increased 150% YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1946563/000121390023077357/0001213900-23-077357-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1946563/000121390023077357/ea185353-8k_60degrees.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-077357

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer